Trial Profile
A phase II trial of tri-week cycle TS-1+L-OHP+Trastuzumab combination therapy for HER2 positive advanced or recurrent gastric cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2018
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 24 May 2016 New trial record